TobaccoReporter logo

Tag: Nicotine Pouches

  • Quitting Smoking Motivated Nearly Half of Pouch Users: Study

    Quitting Smoking Motivated Nearly Half of Pouch Users: Study

    Haypp Group, the parent company of Nicokick.com and Northerner.com, released its Nicotine Pouch and Oral Nicotine Report 2026, based on purchasing data from more than 172,000 customers and a survey of 2,245 adult nicotine pouch users. The report found that 46% of respondents said quitting smoking, vaping, or both was a reason they first tried nicotine pouches, while 88% had previously used another nicotine product before adopting pouches. The average age of a first-time online nicotine pouch purchaser was 45, and adults aged 55 to 64 represented the fastest-growing customer segment in 2025.

    The report also highlighted differences between online and physical retail channels. Among surveyed customers, 98% recalled completing age verification when purchasing online, compared with 75% for purchases made in physical stores. Respondents who reported obtaining nicotine pouches while underage most commonly cited local shops (52%), friends (23%), and supermarkets (10%), while only 5% reported obtaining them online. Haypp Group said sales through Nicokick.com and Northerner.com increased 22% in 2025 after adjusting for sales interruptions in certain states and supply constraints affecting leading brands. The company noted that the survey reflects the experiences of its own customers and is not intended to represent the broader U.S. nicotine pouch market.

  • Smokeless Only Products Growing in Nicotine Market: Report

    Smokeless Only Products Growing in Nicotine Market: Report

    Smokeless nicotine products, including nicotine pouches, continued to gain share in the U.S. nicotine market, with NielsenIQ and Goldman Sachs data showing the segment up more than 8% year over year for the 52 weeks ended May 30. While cigarettes still accounted for nearly 70% of the total nicotine category, sales declined 2.4%. Cigars fell about 1%, and vapes recorded double-digit declines. Grand View Research projects U.S. nicotine pouch sales to grow at a compound annual growth rate of nearly 25% through 2033, positioning the segment as the fastest-growing area within smokeless tobacco.

    The report said market concentration remains high, with Altria Group, British American Tobacco plc, and Swedish Match accounting for more than 90% of smokeless nicotine sales.

  • ALP Plans Expansion into 11 International Markets

    ALP Plans Expansion into 11 International Markets

    ALP announced that it will launch online sales for its nicotine pouches in 11 international markets starting in July, CEO Lorenzo De Plano told Reuters. De Plano said ALP, co-owned by Tucker Carlson and Turning Point Brands, is currently the fourth- or fifth-largest nicotine pouch brand in the United States with roughly 2% market share, and plans to expand its European presence to become the second-largest brand in the European Union by 2030. The rollout will begin in Britain, Ireland, Greece, Switzerland, and Romania in July, followed by additional launches across the Czech Republic, Poland, Portugal, Spain, Sweden, and Denmark later in 2026, with in-store retail expansion in the U.K. targeted for 2027.

    The company said it has secured manufacturing capacity in Lithuania for 20 million units in 2026 and 50 million units in 2027, and is also expanding supplier agreements to support production and distribution growth. ALP also entered a marketing partnership with former UFC champion Conor McGregor to support international expansion efforts.

  • Health Canada Issues Recall for Zyn, Siberia Pouches

    Health Canada Issues Recall for Zyn, Siberia Pouches

    Health Canada issued a nationwide recall for Siberia and ZYN nicotine pouches last week, saying the products are being sold without market authorization. The recall covers Siberia 35 mg pouches and Zyn 6 mg varieties across multiple flavors and all lots, with officials classifying it as a Type II risk, meaning potential temporary health effects but low likelihood of serious harm.

    Consumers are advised to check whether their products are affected, contact their healthcare provider before stopping use, and report any adverse effects or safety concerns to Health Canada, which is also directing users to the recalling firm for further information.

  • Nicotine Pouch Use Surging with Young Canadians

    Nicotine Pouch Use Surging with Young Canadians

    New research from the Ontario Tobacco Research Unit suggests nicotine pouch use among young Canadians has surged dramatically, with more than one-third (34.8%) of respondents aged 17 to 27 reporting they had tried the products by 2026, up from 7.6% in 2022. The longitudinal study, which tracks approximately 3,400 young Canadians, found recent use also climbed sharply, with the share of respondents reporting nicotine pouch use in the previous month rising from 1% to 8.5% over the same period. Researchers said the rapid growth was unexpected and noted that only about one-third of pouch users were cigarette smokers, indicating substantial uptake among non-smokers.

    The findings come as debate continues over Canada’s restrictions on nicotine pouches, which were limited to pharmacy sales in 2024. Health advocates cited the study as evidence supporting strict regulation to prevent youth uptake, while industry representatives and some conservative politicians have argued that broader access could help adult smokers switch from cigarettes and reduce illicit market activity. The research also found that 97% of pouch users had previously tried vaping, with use particularly high among males and in Alberta, underscoring concerns that nicotine pouches are emerging as a fast-growing category among younger consumers.

  • Pouch Popularity Forcing Retailers to Reshape the Backbar

    Pouch Popularity Forcing Retailers to Reshape the Backbar

    According to an analysis by industry publication CSStoreDecisions, convenience retailers are increasingly reshaping tobacco and nicotine category strategies as declining cigarette volumes, rapid growth in nicotine pouches, evolving FDA regulations and shifting consumer preferences transform the backbar. While cigarettes remain the category’s primary revenue driver, retailers reported growing segmentation between premium brands and lower-priced fourth-tier offerings as price-sensitive consumers seek value. Meanwhile, oral nicotine pouches continue to be the industry’s strongest growth segment, driven by consumer migration from cigarettes and traditional smokeless products, aggressive promotions, and expanding flavor and strength options.

    Retailers interviewed by the publication said regulatory uncertainty and rapidly changing manufacturer priorities are forcing constant adjustments to shelf space and assortment decisions. Vape sales have stabilized following years of disruption and increased FDA enforcement, while traditional smokeless tobacco continues to face structural declines as its consumer base ages. Industry operators emphasized that success increasingly depends on localized merchandising, compliance, disciplined pricing and balancing established tobacco products with fast-growing modern nicotine alternatives, particularly as consumer behavior becomes more fluid across multiple product categories.

  • Zest Gets Injunction Against FDA for Pouches

    Zest Gets Injunction Against FDA for Pouches

    Zest Brands LLC announced that it secured a preliminary injunction from the U.S. District Court for the Middle District of Florida, allowing its ZEO Universe nicotine pouch products to remain on the U.S. market while the company challenges an FDA Refuse-to-File (RTF) decision related to its May 2022 Premarket Tobacco Product Applications. The injunction temporarily stays the FDA’s action as the case proceeds through the courts.

    According to the company, the court found Zest Brands is likely to succeed on claims that the FDA failed to adequately assess the impact of its 2021 PMTA regulations on small businesses, as required under the Regulatory Flexibility Act. The court also indicated that aspects of the agency’s actions may have been “arbitrary and capricious.” Zest said it remains committed to working with the FDA to complete the PMTA process and is currently in discussions with strategic and financial partners to support future growth.

  • 19 AGs Urge F1 to Ban Nicotine Sponsorships

    19 AGs Urge F1 to Ban Nicotine Sponsorships

    A coalition of attorneys general from 19 states and jurisdictions has urged Formula 1 and the Fédération Internationale de l’Automobile (FIA) to end all sponsorships involving tobacco and nicotine products, including nicotine pouches. In a letter sent June 8, the coalition argued that nicotine-related sponsorships connected to Formula 1 teams and events could expose younger audiences to marketing for addictive products and undermine longstanding public health efforts aimed at reducing youth nicotine use.

    The letter cites Formula 1’s growing youth audience and increasing reach through social media, streaming platforms, and partnerships with consumer brands as factors heightening concern over nicotine product promotion. The coalition also referenced the 1998 Tobacco Master Settlement Agreement and noted that more than 160 public health organizations made a similar appeal earlier this year, calling on Formula 1 to eliminate tobacco- and nicotine-related sponsorships from the sport.

  • Pentagon’s Nicotine Policy Called into Question

    Pentagon’s Nicotine Policy Called into Question

    A Stars and Stripes editorial published last week argues that the U.S. Department of Defense is facing a “nicotine policy disconnect” in its ranks, highlighting what it describes as inconsistent messaging across leadership and clinical guidance. The piece’s author, Timothy Vermillion, a clinical social worker, said that roughly 30% of active-duty service members use nicotine, framing it as an entrenched feature of military life rather than a behavior likely to be eliminated through abstinence-based policy alone. The article criticizes January DOD clinical guidelines that emphasize quitting and raise concerns about vaping while largely omitting nicotine pouches, arguing this leaves a gap between policy and on-the-ground behavior.

    The commentary also points to senior military leadership acknowledging nicotine use in operational environments and contrasts that with what it calls outdated or unrealistic cessation-focused guidance. It argues that combustible tobacco remains the primary health risk and that harm reduction approaches—particularly switching to non-combustible products such as nicotine pouches—are underrepresented in official guidance. The article concludes that the DOD must better align clinical policy with operational reality to maintain credibility, support readiness, and address long-term health outcomes for service members.

  • FDA Releases Environmental Review for Oral Nicotine Products

    FDA Releases Environmental Review for Oral Nicotine Products

    Today (May 21), the U.S. Food and Drug Administration published a programmatic environmental assessment covering nicotine pouches and other oral nicotine products reviewed through the premarket tobacco product application (PMTA) process. The assessment applies to products categorized as “other,” including nicotine pouches, lozenges, tablets, gums, discs, dissolvable tobacco products, and nicotine-infused products, while excluding traditional smokeless tobacco products such as snus, dip, and chewing tobacco.

    The FDA concluded that the environmental impact of these products is generally minimal, citing the absence of airborne emissions during use and relatively limited environmental contamination from product waste. According to the agency, these products reduce or eliminate secondhand and thirdhand exposure risks compared with combustible products, while the waste generated contains comparatively fewer harmful chemicals that persist or bioaccumulate in the environment.

    The agency said the assessment is intended to support transparency and may be referenced by FDA reviewers evaluating individual product applications. However, the FDA emphasized that authorization decisions will continue to be made on a case-by-case basis based on the specific scientific evidence submitted for each product.